Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (PPBT) generates frequent news as a clinical-stage oncology company developing therapies that, according to its own reports, target tumor immune evasion and drug resistance. Investors and observers following PPBT news can track updates on its CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219, as well as financing and listing developments.
Recent press releases highlight CAPTN-3 as a key source of news. The company has announced manufacturing milestones for IM1240, the first tri-specific antibody from the platform targeting 5T4, CD3 and NKG2A, including achievement of a commercially viable yield. Additional updates describe non-human primate toxicology data for IM1240, with Purple Biotech reporting an expanded therapeutic window compared with a non-capped comparator and a pharmacokinetic profile characterized by increased systemic exposure and prolonged half-life in that study.
News flow also covers preclinical data presentations at scientific meetings such as the ESMO Immuno-Oncology Congress and other conferences. These releases describe anti-tumor activity of IM1240 and IM1305 in models resistant to prior PD-1 therapy, transcriptomic analyses supporting the inclusion of an NKG2A arm, and ex vivo results in patient-derived tumor biopsies. Such items provide context on how the company positions CAPTN-3 within immuno-oncology research.
Beyond CAPTN-3, Purple Biotech issues updates on CM24 Phase 2 data in pancreatic ductal adenocarcinoma and on NT219, including an intention to grant a European patent for NT219 combination regimens and progress of a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Financial and corporate news includes quarterly results, public offerings of American Depositary Shares and warrants, at-the-market offering agreements, and Nasdaq minimum bid price notifications.
Readers who monitor PPBT news can use this page to follow scientific milestones, regulatory and clinical progress, capital-raising transactions, and listing-related announcements directly sourced from company press releases and SEC-furnished documents.
Purple Biotech (NASDAQ/TASE: PPBT) reported positive final results from its randomized Phase 2 study of CM24 in second-line pancreatic cancer. The study evaluated CM24, combined with nivolumab and Nal-IRI/5FU/LV chemotherapy, showing significant improvements across efficacy endpoints. In a biomarker-enriched patient population, the treatment demonstrated a 79% reduction in death risk (HR 0.21, P = 0.04) with 5.1 months median OS improvement, and over 90% reduction in progression risk (HR < 0.1, P = 0.003) with 2.9 months median PFS improvement. The company plans to proceed with a Phase 2b study in multiple selected indications, targeting patients based on biomarkers.
Purple Biotech (NASDAQ/TASE: PPBT) reported Q3 2024 financial results and clinical updates. The company expects topline data from Phase 2 CM24 pancreatic cancer trial by end of 2024. New biomarker data showed patients with specific serum CEACAM1 levels demonstrated 79% reduction in death risk. Q3 financial highlights include reduced R&D expenses to $1.3M (71.7% decrease), operating loss of $2.1M (63.2% decrease), and net loss of $0.7M. Cash position stands at $6.3M with runway extending into Q4 2025. The company plans to commence Phase 2 study of NT219 in head and neck cancer in H1 2025.
Purple Biotech has identified serum CEACAM1 as a potential new blood biomarker for its lead oncology candidate CM24. Pancreatic cancer patients with serum CEACAM1 levels between 6K-15K pg/mL showed significantly improved outcomes when treated with CM24 and nivolumab combined with chemotherapy. The treatment demonstrated a 79% reduction in death risk, improving median overall survival from 3.6 to 8.7 months, and progression-free survival to 4.6 months. CM24, a CEACAM1 inhibitor, is currently in Phase 2 trials with topline results expected in Q4 2024.
Purple Biotech presented new data for its CAPTN-3 platform at the EORTC-NCI-AACR Symposium. The platform demonstrates sustained tumor regression in triple negative breast cancer models and dose-dependent activity in non-small cell lung cancer. The lead tribody IM1240 showed 5T4-dependent cytokine release with improved safety profile through conditional activation. The platform enables development of tri-specific antibodies targeting both T cells and NK cells to fight cancer, with potential first human clinical studies by 2026. The technology showed synergistic effects in tumor suppression and demonstrated plug-and-play capabilities for targeting different cancer types.
Purple Biotech (NASDAQ/TASE: PPBT) has been selected to present data on its CAPTN-3 platform at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from October 23-25, 2024. The poster, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be presented by Dr. Hadas Reuveni, VP R&D of Purple Biotech.
CAPTN-3 is a first-in-class platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells with tumors, creating an enhanced immune response against cancer. The company's lead candidate, IM1240, targets 5T4, a tumor-associated antigen overexpressed in various solid tumors and linked to poor clinical outcomes. 5T4's specific expression pattern in cancer cells makes it an ideal target for therapeutic approaches in lung, gastric, head and neck, and other cancers.
Purple Biotech (NASDAQ/TASE: PPBT) reported positive interim data from its Phase 2 study of CM24, its lead oncology therapeutic candidate, for pancreatic ductal adenocarcinoma (PDAC) treatment. Key findings include:
1. High CEACAM1 and low PDL1 expression in tumors associated with improved overall survival (OS).
2. Improved OS for patients with serum neutrophil extracellular trap (NET) marker myeloperoxidase (MPO).
3. NETs proposed as a novel mechanism of action and potential biomarker for CM24-based therapy.
4. Data supports potential for biomarker-led studies and exploration of CM24's efficacy in other cancers.
The study evaluates CM24 combined with nivolumab and chemotherapy as a second-line PDAC treatment. Topline data expected in Q4 2024.
Purple Biotech (NASDAQ/TASE: PPBT) has been selected to present data on its lead oncology drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research in Boston, Massachusetts, from September 15-18, 2024. The poster presentation, scheduled for September 17, will focus on exploratory biomarker evaluation from the randomized Phase 2 study of CM24 in combination with nivolumab and chemotherapy for advanced/metastatic pancreatic cancer.
The ongoing Phase 2 study involves 63 patients across 18 centers in the U.S., Spain, and Israel. Interim data presented at the 2024 ASCO Annual Meeting showed improvements in overall survival, progression-free survival, and objective response rate in the experimental arm compared to standard of care. Topline data from this study are expected in Q4 2024.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies for tumor immune evasion and drug resistance, will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. The company's executive management will engage in a virtual Fireside Chat presentation and one-on-one meetings with institutional investors.
Key points:
- Virtual Fireside Chat available on-demand from September 9 at 7:00 AM ET
- Presentation accessible for 30 days on Purple Biotech's website
- CEO Gil Efron to conduct in-person meetings at the Lotte New York Palace Hotel
- Investors can register for the conference at www.hcwevents.com/annualconference
Purple Biotech (NASDAQ/TASE: PPBT) reported positive interim data from its Phase 2 CM24 pancreatic cancer study at ASCO 2024. The CM24+nivolumab+NAL-IRI/5FU/LV combination showed improvements in overall survival, progression-free survival, and objective response rate compared to standard-of-care. The company is evaluating expanding CM24's clinical program based on its novel CEACAM1 target on Neutrophil Extracellular Traps.
Financial highlights for Q2 2024 include:
- R&D expenses decreased 35.1% to $2.4 million
- Operating loss decreased 31.4% to $3.5 million
- Net loss decreased to $2.4 million ($0.09 per ADS)
- Cash runway extended to Q3 2025
Purple Biotech expects additional interim data in Q3 2024 and final topline results in Q4 2024.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage oncology company, has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The company now has until January 21, 2025, to meet this requirement, which involves maintaining a closing bid price of at least $1.00 for its American Depositary Shares (ADSs) for a minimum of 10 consecutive business days. This extension does not immediately affect Purple Biotech's listing on Nasdaq or the Tel Aviv Stock Exchange. The company will monitor its ADS price and consider options to regain compliance within the given timeframe.